Analysts think MBX stock price could increase by 163%
Aug 16, 2025, 11:25 AM
-2.11%
What does MBX do
MBX Biosciences, a clinical-stage biopharmaceutical company based in Carmel, Indiana, focuses on precision peptide therapies for endocrine and metabolic disorders and went public on September 13, 2024. Its product candidates include MBX 2109, MBX 1416, and MBX 4291, targeting various hormone-related conditions.
7 analysts think MBX stock price will increase by 163.23%. The current median analyst target is $38.76 compared to a current stock price of $14.72. The lowest analysts target is $30.30 and the highest analyst target is $46.20.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
